We are live on ! Find out more

Teleflex

TFX

Market cap $5.32B

125.59 USD

-2.41

1.88%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

125.59

0.00

0%

1 day

-1.88%

5 days

-5.73%

1 month

-5.62%

3 months

0.5%

6 months

15.22%

Year to date

2.61%

1 year

-0.02%

5 years

-67.43%

10 years

-28.38%

About: Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.

Employees: 15,500

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 55.6%

Negative 11.1%

Zacks Investment Research

Here's Why Teleflex (TFX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Teleflex (TFX) is a Strong Value Stock

Zacks Investment Research

5 Low P/B Stocks That Offer Attractive Value and Growth

TFX, CNC, ENS, ROCK and FAF stand out among five low P/B stocks offering attractive value and promising growth prospects.

5 Low P/B Stocks That Offer Attractive Value and Growth

Zacks Investment Research

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

TFX vs. PEN: Which Stock Is the Better Value Option?

Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portf.

Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors

Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a.

Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026

Zacks Investment Research

Should You Add Teleflex Stock to Your Portfolio Now?

TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.

Should You Add Teleflex Stock to Your Portfolio Now?

Zacks Investment Research

TFX or PEN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

TFX or PEN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?

Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.

Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?

Zacks Investment Research

Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?

TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.

Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?

Teleflex: Portfolio Surgery Creates A Better Medtech Compounder

Teleflex is transforming into a focused procedural technology platform, divesting lower-growth units and reinvesting in high-acuity Vascular and Surgical segments. TFX's Vascular and Surgical segments are generating high-single-digit growth, while Interventional segment weakness is attributed to temporary integration challenges. Proceeds from divestitures are funding debt reduction and substantial share repurchases, enhancing per-share earnings potential and financial flexibility.

Teleflex: Portfolio Surgery Creates A Better Medtech Compounder

See News Rankings

Price charts implemented using Lightweight Charts™